We are live on ! Find out more
GILD icon

Gilead Sciences

1,263 hedge funds and large institutions have $116B invested in Gilead Sciences in 2014 Q2 according to their latest regulatory filings, with 163 funds opening new positions, 527 increasing their positions, 461 reducing their positions, and 83 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 163 | Existing positions closed: 83

46% more funds holding in top 10

Funds holding in top 10: 112164 (+52)

14% more repeat investments, than reductions

Existing positions increased: 527 | Existing positions reduced: 461

6% more funds holding

Funds holding: 1,1891,263 (+74)

0% less capital invested

Capital invested by funds: $116B → $116B (-$569M)

24% less call options, than puts

Call options by funds: $2B | Put options by funds: $2.62B

Holders
1,263
Holders Change
+74
Holders Change %
+6.22%
% of All Funds
36.28%
Holding in Top 10
164
Holding in Top 10 Change
+52
Holding in Top 10 Change %
+46.43%
% of All Funds
4.71%
New
163
Increased
527
Reduced
461
Closed
83
Calls
$2B
Puts
$2.62B
Net Calls
-$624M
Net Calls Change
+$552M
Name Holding Trade Value Shares
Change
Change in
Stake
UCFA
451
United Capital Financial Advisors
Texas
$9.07M +$2.62M +33,640 +44%
MIM
452
Marco Investment Management
Georgia
$8.86M +$736K +9,450 +10%
FTIOP
453
Fiduciary Trust International of Pennsylvania
Pennsylvania
$8.83M +$2.55M +32,770 +44%
CS
454
Cannell & Spears
New York
$8.81M -$11M -140,728 -57%
Hudson Bay Capital Management
455
Hudson Bay Capital Management
Connecticut
$8.74M +$8.2M +105,400 New
BCM
456
Brown Capital Management
Maryland
$8.7M +$96.8K +1,243 +1%
PG
457
PEAK6 Group
Illinois
$8.62M -$4.86M -62,473 -38%
Neuberger Berman Group
458
Neuberger Berman Group
New York
$8.56M +$1.97M +25,307 +32%
RIG
459
Roosevelt Investment Group
New York
$8.54M +$2.95M +37,960 +58%
SIM
460
Sentry Investment Management
Wisconsin
$8.52M +$990K +12,714 +14%
ACM
461
Argent Capital Management
Missouri
$8.47M -$970K -12,462 -11%
FIB
462
First Interstate Bank
Montana
$8.45M +$1.73M +22,182 +28%
CC
463
Curian Capital
Colorado
$8.35M -$7.2M -92,558 -48%
CAI
464
Capital Advisors Inc
Oklahoma
$8.31M +$7.8M +100,180 New
PIM
465
Partner Investment Management
California
$8.2M -$5.79M -74,355 -43%
IHL
466
Investment House LLC
California
$8.19M +$107K +1,370 +1%
FA
467
Friess Associates
Delaware
$8.16M +$7.66M +98,380 New
DCM
468
Decatur Capital Management
Georgia
$8.14M -$3.85M -49,400 -33%
TSW
469
Thompson Siegel & Walmsley
Virginia
$8.12M +$7.63M +97,975 New
Janney Montgomery Scott
470
Janney Montgomery Scott
Pennsylvania
$8.1M -$205K -2,633 -3%
SLI
471
Sumitomo Life Insurance
Japan
$8.05M -$1.77M -22,747 -19%
NCGI
472
Next Century Growth Investors
Minnesota
$8.02M -$2.79M -35,851 -27%
NLGIA
473
Nippon Life Global Investors Americas
New York
$7.94M +$2.29M +29,440 +44%
CA
474
CapWealth Advisors
Tennessee
$7.93M +$913K +11,730 +14%
Robeco Institutional Asset Management
475
Robeco Institutional Asset Management
Netherlands
$7.89M +$465K +5,969 +7%

GILD Hedge Fund Activity: Q2 2014 in Review

1,263 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q2 2014, worth a combined $116B — down 0.49% from $116B a quarter earlier.

Buyers outnumbered sellers: 163 funds opened new GILD positions and 83 closed out — a net gain of 80 holders — while 527 added to existing stakes and 461 trimmed.

The largest buyer was Capital Research Global Investors, adding an estimated $1.16B. The largest seller was BNP Paribas Financial Markets, cutting an estimated $3.85B.

  • 1,263 institutional investors held Gilead Sciences (GILD) as of Q2 2014, up from 1,189 in Q1 2014.
  • Funds reported $116B of Gilead Sciences stock for Q2 2014, down 0.49% quarter-over-quarter.
  • 163 funds opened new Gilead Sciences positions in Q2 2014 and 83 closed out, a net change of +80 holders.
  • The largest Gilead Sciences buyer in Q2 2014 was Capital Research Global Investors, an estimated $1.16B added.
  • The largest Gilead Sciences seller in Q2 2014 was BNP Paribas Financial Markets, an estimated $3.85B sold.

Based on aggregated 13F filings for Q2 2014.